Wednesday, July 8, 2026

pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB

Cellectar Biosciences

Cellectar Biosciences is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker CLRB. Primary therapeutic focus areas include Waldenstrom Macroglobulinemia, Non Small Cell Lung Cancer, B

100 Campus Dr, 207, Florham Park, New Jersey 07932, US HQ
21 Employees
Public company Type
CLRB · NYSE Ticker
Company details
Status
Public
HQ
100 Campus Dr, 207, Florham Park, New Jersey 07932, US
Employees
21
Programs
17
Drugs
7
Patents
7
Clinical program

Paclitaxel

Phase 3 · small molecule · Non Small Cell Lung Cancer

Paclitaxel for Non Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Cellectar Biosciences with 1 ClinicalTrials.gov record(s).

← All Cellectar Biosciences projects Phase 3 small molecule completed

Internal code NOV002-C301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cellectar Biosciences
Phase
Phase 3
Modality
small_molecule
Indication
Non Small Cell Lung Cancer
Status
completed
Trials
1